RBM20 and Cardiomyopathy by Watanabe, Takeshi et al.
REVIEW
published: 28 November 2018
doi: 10.3389/fmolb.2018.00105
Frontiers in Molecular Biosciences | www.frontiersin.org 1 November 2018 | Volume 5 | Article 105
Edited by:
Naoyuki Kataoka,
The University of Tokyo, Japan
Reviewed by:
Ihab Younis,
Carnegie Mellon University in Qatar,
Qatar
Claudia Ghigna,






This article was submitted to
RNA,
a section of the journal
Frontiers in Molecular Biosciences
Received: 02 October 2018
Accepted: 09 November 2018
Published: 28 November 2018
Citation:
Watanabe T, Kimura A and
Kuroyanagi H (2018) Alternative
Splicing Regulator RBM20 and
Cardiomyopathy.




Takeshi Watanabe 1,2, Akinori Kimura 3,4 and Hidehito Kuroyanagi 1,4,5*
1 Laboratory of Gene Expression, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan,
2Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Science, Tokyo Medical and Dental
University (TMDU), Tokyo, Japan, 3Division of Pathology, Department of Molecular Pathogenesis, Medical Research Institute,
Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 4 Laboratory for Integrated Research Projects on Intractable
Diseases Advanced Technology Laboratories, Medical Research Institute, Tokyo Medical and Dental University (TMDU),
Tokyo, Japan, 5Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los
Angeles, CA, United States
RBM20 is a vertebrate-specific RNA-binding protein with two zinc finger (ZnF) domains,
one RNA-recognition motif (RRM)-type RNA-binding domain and an arginine/serine
(RS)-rich region. RBM20 has initially been identified as one of dilated cardiomyopathy
(DCM)-linked genes. RBM20 is a regulator of heart-specific alternative splicing and
Rbm201RRM mice lacking the RRM domain are defective in the splicing regulation. The
Rbm201RRM mice, however, do not exhibit a characteristic DCM-like phenotype such as
dilatation of left ventricles or systolic dysfunction. Considering that most of the RBM20
mutations identified in familial DCM cases were heterozygous missense mutations in
an arginine-serine-arginine-serine-proline (RSRSP) stretch whose phosphorylation is
crucial for nuclear localization of RBM20, characterization of a knock-in animal model
is awaited. One of the major targets for RBM20 is the TTN gene, which is comprised
of the largest number of exons in mammals. Alternative splicing of the TTN gene is
exceptionally complicated and RBM20 represses >160 of its consecutive exons, yet
detailed mechanisms for such extraordinary regulation are to be elucidated. The TTN
gene encodes the largest known protein titin, a multi-functional sarcomeric structural
protein specific to striated muscles. As titin is the most important factor for passive
tension of cardiomyocytes, extensive heart-specific and developmentally regulated
alternative splicing of the TTN pre-mRNA by RBM20 plays a critical role in passive
stiffness and diastolic function of the heart. In disease models with diastolic dysfunctions,
the phenotypes were rescued by increasing titin compliance through manipulation of the
Ttn pre-mRNA splicing, raising RBM20 as a potential therapeutic target.
Keywords: RBM20, dilated cardiomyopathy (DCM), alternative splicing, isoform switching, mutation,
arginine/serine (RS)-rich region, titin, nuclear localization
INTRODUCTION
Cardiomyopathy is a myocardial disease with cardiac dysfunction. Cardiomyopathy is roughly
classified as genetic cardiomyopathy including hypertrophic cardiomyopathy (HCM), and mixed
(genetic and acquired) cardiomyopathy such as dilated cardiomyopathy (DCM; Dadson et al.,
2017). HCM is a disease in which hypertrophy of the ventricle occurs despite the absence of high
blood pressure or valvular disease that cause ventricular hypertrophy (Elliott, 2014). More than half
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of the HCM patients carry mutations in one of eight sarcomere
genes (Sabater-Molina et al., 2018). DCM is another common
form of cardiomyopathy, affecting ∼1 in 250–500 in general
population (McKenna et al., 2017) and characterized by left
ventricular dilatation and systolic dysfunction in the absence
of abnormal loading conditions or coronary artery disease
(Rampersaud et al., 2011; McCartan et al., 2012). Mortality rate
of DCM is high as a result of heart failure (Kirk et al., 2009).
Among the idiopathic DCM cases, 20–35% are familial, with
autosomal dominant inheritance in most cases (Kimura, 2016).
A next generation sequencing method has recently identified
more than 400 potentially causative mutations in 60 genes
both in familial and sporadic DCM cases (Pérez-Serra et al.,
2016). These DCM-associated genes can be classified into various
functional groups such as muscle contraction, Ca2+ handling,
and nuclear function. Such molecular genetic complexity makes
it difficult to elucidate the mechanisms bringing about the
common phenotypes of DCM (Hershberger et al., 2013). Among
the DCM-linked mutations, 25% were mapped to the TTN
gene (Herman et al., 2012; Hershberger et al., 2013; Fatkin and
Huttner, 2017). The human TTN gene has 364 exons, the largest
number of exons in a single gene in mammals, 363 of which
are coding. The TTN gene encodes the largest known protein
titin, a multi-functional sarcomeric structural protein specific to
striated muscles (Gigli et al., 2016). Titin plays a major role in
passive tension of cardiomyocytes (Hidalgo and Granzier, 2013).
The TTN pre-mRNA undergoes extensive alternative splicing,
leading to tissue-specific and developmentally regulated titin
isoforms.
RBM20, encoding RNA Binding Motif Protein-20 (RBM20)
has initially been identified as one of the DCM-linked genes
(Brauch et al., 2009). Genetic abnormalities in RBM20 have been
identified in about 2–3% of familial and sporadic DCM cases (Li
et al., 2010; Refaat et al., 2012; Kayvanpour et al., 2017). Recently,
RBM20 has been identified as a crucial RNA-binding protein that
controls the splicing of TTN (Guo et al., 2012). However, roles
of RBM20 in the pathophysiology of DCM is still unclear. Only
a few studies have addressed molecular mechanisms of splicing
regulation by RBM20, and are controversial. In this review,
we summarize the literature on RBM20 and discuss effects of
mutations found in the DCM patients. We also summarize
recent attempts to manipulate the RBM20 functions in various
disease models. Finally, we will discuss open questions about the
functions of RBM20 and its relevance to DCM.
STRUCTURE OF RBM20
RBM20 is a vertebrate-specific RNA-binding protein (Zerbino
et al., 2018). The human RBM20 gene resides on chromosome
10 and is composed of 14 exons. Human RBM20 protein consists
of 1,227 amino acid residues and is relatively large for a splicing
regulator, yet it has only three conserved recognizable functional
domains: two zinc finger (ZnF) domains and one RNA-
RecognitionMotif (RRM)-type RNA-binding domain (Figure 1).
Sequence alignment of RBM20 proteins from various vertebrate
species revealed three other conserved regions (Guo et al., 2012;
Murayama et al., 2018; Zahr and Jaalouk, 2018): a leucine (L)-
rich region at theN-terminus, an arginine/serine (RS)-rich region
just downstream from the RRM domain and a glutamate (E)-
rich region between the RS-rich region and the ZnF2 domain
(Figure 1).
Vertebrates have two proteins homologous to RBM20;
matrin3, and ZNF638 have two RRM domains sandwiched by
two ZnF domains and these domains are most related to those
of RBM20 (Coelho et al., 2016). RBM20 is highly expressed in
the heart and the skeletal muscle (Filippello et al., 2013), whereas
matrin3 and ZNF638 are widely expressed across different cell
types (Coelho et al., 2016).
RBM20 MUTATIONS IN DCM PATIENTS
The RBM20 mutations identified so far in familial as well
as sporadic DCM cases are listed in Table 1. The list clearly
revealed that almost all of theRBM20mutations are heterozygous
missense mutations and are enriched in a hot spot composed
of an arginine-serine-arginine-serine-proline (RSRSP) stretch at
aa 634–638 in the RS-rich region (Table 1; Figure 1B). This
situation is unusual considering that most of the missense
mutations were mapped to the RRM domains in our previous
genetic screening for loss- or reduction-of-function mutants for
splicing factors (Kuroyanagi et al., 2006, 2007, 2013). We will
discuss later how these mutations would affect the function of
RBM20.
ALTERNATIVE SPLICING OF THE TTN
GENE
Single titin protein spans half of sarcomere, with its N- and C-
termini in the Z-disk and the M-band, respectively (Figure 2).
It is composed of four structural and functional regions located
in Z-disk, I-band, A-band, and M-band (Figure 2A; Wang
et al., 1979). Titin is attached to the Z-disk and the thick
filament via its Z-disk and A-band segments, respectively (Wang
et al., 1979). The I-band region is not attached to any of the
solid structures and therefore functions as a molecular spring
that generates passive tension when sarcomeres are stretched
during diastole (Horowits et al., 1986). In the elastic I-band
region of titin, there are six domains from the N-terminus as
follows: proximal immunoglobulin (Ig) repeat domain, N2B-
unique element, middle Ig repeat domain, N2A-unique element,
proline-glutamate-valine-lysine (PEVK) domain and distal Ig
repeat domain (Figure 2A; Labeit et al., 1990; Bang et al., 2001;
Lange et al., 2005).
The TTN gene can potentially produce an mRNA of more
than 100 kb. Deduced from its sequence, the predicted full-
length mRNA would produce a protein composed of ∼39,000
amino acid residues whose molecular weight (MW) is 4.2 MDa
(Bang et al., 2001; Guo and Sun, 2017). However, when SDS-
PAGE was performed on rat myocardium samples, six titin
isoforms of roughly 3.0 to 3.9 MDa were mainly identified
(Zhu and Guo, 2017). While almost all exons encoding the Z-
disk, A-band and M-band regions are constitutively included,
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FIGURE 1 | Structure of the RBM20 protein. (A) Schematic domain structure of the human RBM20 protein. Names and positions of the domains are indicated.
E-rich, glutamate-rich region; L-rich, leucine-rich region; RRM, RNA-recognition motif domain; RS-rich, arginine/serine-rich region; ZnF, zinc finger domains. (B) Amino
acid sequence alignment of the RS-rich region of RBM20 proteins from human, mouse, rat, chicken and frog. Amino acid residues that match the human RBM20
residues are shaded. The RSRSP stretch is in red. Asterisks indicate evolutionarily conserved arginine (R), serine (S), and proline (P) residues.
many exons encoding the elastic I-band region are alternatively
spliced in tissue-specific and developmentally regulated manners
(Figure 2B). Exons encoding the proximal and distal Ig repeat
domains are constitutively included in all isoforms. Exon 49,
encoding the N2B-unique element, is a long exon (2,646 bp in
human) and is specifically included in the heart but excluded in
the skeletal muscle. Exon 50 is a constitutive exon and encodes
an Ig domain. Exons 51–101 are alternatively spliced and encode
the middle Ig repeat domain. Exons 102–108 and exons 109–224
encode the N2A-unique element and PEVK domain, respectively
(Lewinter et al., 2007). Among these exons, alternative splicing
of exons encoding the middle Ig repeat domain (exons 51–
100) and the PEVK domain (exons 116–218) are exceptionally
complicated (Guo et al., 2010). In the myocardium, two major
titin isoforms are expressed; the shorter N2B isoform contains
only the N2B-unique element among the variable domains; the
longer N2BA isoforms including fetal types called fetal cardiac
titin (FCT) contain the N2B- and N2A-unique elements and
a variable length of the middle Ig repeat domain (Figure 1).
In the skeletal muscle, the N2A isoform containing all of the
variable domains except for the N2B-unique element is expressed
(Lewinter et al., 2007; Guo and Sun, 2017; Figure 2B).
RBM20 is the major regulator of the heart-specific TTN pre-
mRNA splicing. In the spontaneous Rbm20 mutant rat strain
lacking a 95-kb region spanning from exons 2–14, titin N2B
is no longer expressed while N2BA is predominantly expressed
in heterozygotes, and an extraordinarily large isoform N2BA-
G is exclusively expressed in homozygotes (Guo et al., 2012);
Figure 2B. The N2BA isoform is also predominantly expressed
in the heart of a DCM patient carrying a heterozygous missense
mutation S635A in the RBM20 gene (Guo et al., 2012). In
a human heart-failure cohort, low expression of endogenous
RBM20 was correlated with the splicing pattern of the TTN gene
(Maatz et al., 2014). These reports indicated that splicing control
of many of the TTN exons is extremely sensitive to the amount
of functional RBM20 protein.
RBM20 REGULATES HEART-SPECIFIC
ALTERNATIVE SPLICING
High-throughput RNA sequencing (RNA-seq) of cardiac
transcriptomes from the Rbm20-null rats and human DCM
patients with and without mutations in RBM20 revealed
31 genes whose alternative splicing is RBM20-dependent
in both rats and humans (Guo et al., 2012). Crosslinking
and immunoprecipitation coupled with RNA-seq (CLIP-seq)
experiments of endogenous RBM20 in rat cardiomyocytes
identified 80 direct target exons in 18 genes (Maatz et al., 2014).
RBM20 predominantly represses cassette exons including those
in the Ttn and Ryr2 genes by binding to upstream and/or
downstream intron(s) of the target exons (Li et al., 2013;
Maatz et al., 2014). Mutually exclusive exons are also enriched
among the RBM20 target exons (Guo et al., 2012; Maatz et al.,
2014). For instance, RBM20 represses exons 15 and 16 and
promotes inclusion of exon 14 in the Camk2d gene encoding
Ca2+/calmodulin-dependent protein kinase II-δ (CaMKII-δ);
RBM20 represses exons 5–7 and promotes inclusion of exon
4 in the Ldb3 gene encoding Lim domain binding protein
3 (LDB3).
A UCUU core element has been identified as a precise
RNA recognition element (RRE) for RBM20 by photoactivatable
ribonucleoside-enhanced crosslinking and immunoprecipitation
(PAR-CLIP) experiments with epitope-tagged human RBM20 in
human embryonic kidney 293 (HEK293) cells and by the CLIP-
seq experiments with rat cardiomyocytes (Maatz et al., 2014).
In the Ttn pre-mRNA, RBM20-binding sites were identified
in many of the introns between exon 50 and exon 219 but
were almost excluded from the constitutively spliced regions
(Maatz et al., 2014). The introns in the alternatively spliced
regions were retained in the wild-type rat heart (Li et al.,
2013), suggesting that RBM20 represses exons 51–218 by
inhibiting excision of most if not all of the introns in this
region.
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TABLE 1 | RBM20 mutations identified in DCM patients and their symptoms other than ventricular dilatation.




AF VA HF or
SD
Brauch et al., 2009 RS-rich R634Q Familial Hetero Unknown Defective 0/10 1/10 0/10
R636S Familial Hetero Unknown Defective 1/13 0/13 2/13
R636H Familial Hetero Unknown Unknown 0/2 0/2 0/2
S637G Familial Hetero Unknown Defective 0/4 1/4 1/4
P638L Familial Hetero Unknown Defective 2/16 6/16 5/16
Li et al., 2010 RRM V535I Sporadicb Hetero Unknown Unaffected 1/1 0/1 1/1
RS-rich R634Q Sporadic Hetero Unknown Defective 0/1 0/1 1/1
R634W Familial Hetero Exclusion from
nucleusc
Defective 0/1 0/1 0/1
R636C Familial Hetero Unknown Unknown 1/2 1/2 1/2
R636H Familial Hetero Unknown Unknown 0/3 1/3 1/3
Others R716Q Familiald Hetero Unknown Defective 0/18 0/18 3/18
Millat et al., 2011 RS-rich S637G Familial Hetero Unknown Unknown Unknown Unknown Unknown
Refaat et al., 2012 L-rich L83I Sporadic Hetero Unknown Unknown 0/1 0/1 Unknown
RS-rich P638L Sporadic Hetero Unknown Defective 1/1 0/1 Unknown
E-rich D888N Sporadic Hetero Unaffectedc Unknown 1/1 0/1 Unknown
Others S455L Sporadic Hetero Unknown Unknown 0/1 0/1 Unknown
R703S Sporadic Hetero Unknown Unknown 1/1 0/1 Unknown
G1031X Sporadic Hetero Unaffectedc Effective 0/1 0/1 Unknown
P1081R Sporadic Hetero Unaffectedc Unknown 0/1 0/1 Unknown
E1206K Sporadic Hetero Unaffectedc Unknown 0/1 0/1 Unknown
Guo et al., 2012 RS-rich S635A Sporadic Hetero Exclusion from
nucleusc
Defective Unknown Unknown Unknown
Wells et al., 2013 RS-rich R636H Familial Hetero Unknown Unknown Unknown Unknown Unknown
Chami et al., 2014 RS-rich R636H Familial Hetero Unknown Unknown Unknown Unknown Unknown
Zhao et al., 2015 Others R1182H Unknown Hetero Unknown Unknown Unknown Unknown Unknown
Beqqali et al., 2016 E-rich E913K Familial Hetero Protein
destabilization
Defective Unknown Unknown 4/9



















Note that residues within the RSRSP stretch in the RS-rich region are in red.
aEffect of RBM20 mutations on alternative splicing regulation of the TTN gene was assessed by using TTN splicing reporters (Guo et al., 2012; Murayama et al., 2018).
bThe patient also has an A698T mutation in LDB3.
cEffect of RBM20 mutations on RBM20 nuclear localization and phosphorylation of the RSRSP stretch was assessed by using mouse cDNAs with equivalent mutations (Murayama
et al., 2018).
d Incomplete penetrance.
eThe patient is homozygous for the RBM20 mutation due to uniparental disomy, whereas his mother is heterozygous and asymptomatic.
AF, atrial fibrillation; HF, heart failure; SD, sudden death; VA, ventricular arrhythmias.
THE RSRSP STRETCH IN THE RS-RICH
REGION IS CRUCIAL FOR NUCLEAR
LOCALIZATION OF RBM20
Recently, it has been reported that both of the two serine residues
in the RSRSP stretch are constitutively phosphorylated in cells
and that single amino acid substitutions in the stretch disrupted
nuclear localization of full-length RBM20 protein (Murayama
et al., 2018; Figure 3). Moreover, Rbm20S637A knock-in mouse
mimicking the S635A mutation showed a remarkable effect on
the titin isoform expression like in the Rbm20-null rat strain
(Murayama et al., 2018). These findings indicated that the RSRSP
stretch is a crucial part of the RBM20 nuclear localization signal
(NLS) and that the DCM-linked mutation in the RSRSP stretch
fully disrupted the alternative splicing control by RBM20.
Many of splicing factors such as SR-protein family members
are known to have RS-rich regions or RS domains consisting
of multiple serine-arginine (SR) and arginine-serine (RS)
dipeptides (Zahler et al., 1992). The RS domains of the
SR proteins are extensively phosphorylated on the serine
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FIGURE 2 | Structure of the titin protein isoforms. (A) Schematic domain structure of the titin protein. Names and positions of the domains are indicated.
Corresponding exons are indicated below each domain. Distal Ig, distal Ig repeat domain; Middle Ig, middle Ig repeat domain; N2A, N2A-unique element; N2B,
N2B-unique element; Proximal Ig, proximal Ig repeat domain. (B) Schematic structures of the titin isoforms. Names of the isoforms and the tissues that mainly express
the isoforms are indicated on the left. Dotted lines indicate highly variable alternatively spliced regions. FCT, fetal cardiac titin.
FIGURE 3 | Missense mutations in the RSRSP stretch disrupt the normal functions of RBM20. (Left) In the wild-type, two serine residues in the RSRSP stretch are
phosphorylated and the RBM20 protein is localized in the nucleus, where RBM20 regulates alternative pre-mRNA splicing of its target genes so that cardiac isoforms
of mRNAs are produced. The mRNAs are translated into cardiac protein isoforms with specialized functions. (Right) In the RBM20 missense mutant with a substitution
in the RSRSP stretch, the mutant RBM20 proteins are no longer imported into the nucleus. Pre-mRNAs of the RBM20-target genes are processed into non-cardiac
isoforms of mRNAs, which are then translated into non-cardiac protein isoforms, which may lack the specialized functions and/or exert aberrant functions. The mutant
RBM20 proteins retained in the cytoplasm may also exert aberrant functions. P, phosphorylation.
residues and this phosphorylation plays an important
role in regulating subcellular localization, protein-protein
interaction and splicing regulation activities of the SR
proteins (Xiao and Manley, 1997; Yeakley et al., 1999). It is
therefore reasonable to suggest that the RBM20-mediated
heart-specific alternative splicing is dynamically regulated
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during development and under pathological conditions via
dynamic phosphorylation/dephosphorylation of the RSRSP
stretch.
Many RBM20-interacting proteins have been identified in
HEK293 cells by quantitative stable isotope labeling by amino
acids in cell culture (SILAC)-based proteomics experiments and
some of these interactions were affected by the S635A mutation
(Maatz et al., 2014). Totally distinct subcellular localization of the
wild-type and mutant RBM20 proteins (Murayama et al., 2018)
might be the major cause of this distinct interactomes. Even with
the information about the RBM20 interactome, it is still unclear
how the interaction with these proteins leads to repression or
switching of its target exons.
THE RRM DOMAIN OF RBM20 IS CRUCIAL
FOR SPLICING REGULATION IN VIVO
Molecular mechanisms of RBM20-mediated alternative splicing
have been analyzed mostly by utilizing TTN reporter minigenes
expressed in non-cardiac cells. However, the results from such
studies utilizing distinct reporter minigenes are controversial as
to which of the conserved domains are crucial for the regulation.
Mutations in the RSRSP stretch but not in the RRM domain
affected repression of the 5′ PEVK exons (Guo et al., 2012). The
RRM domain and the E-rich region were crucial for repressing
exon 242 (Liss et al., 2018). The RSRSP stretch and the E-rich
region but not putative RNA-binding domains RRM, ZnF1, or
ZnF2 were crucial for repression of a chimeric exon 51/218
(Murayama et al., 2018). Full-length RBM20 (Maatz et al., 2014)
or the RRM domain alone (Dauksaite and Gotthardt, 2018) does
not necessarily bind to any RNA molecules containing UCUU
element(s) in electrophoretic mobility shift assays (EMSAs).
Therefore, other RNA element(s) and/or other RNA-binding
protein(s) might be involved in the recognition of the authentic
target pre-mRNAs by RBM20.
Functions of the RRM domain in vivo has been assessed
by deleting exons 6 and 7 of the Rbm20 gene in the mouse.
N2BA and N2BA-G isoforms of titin proteins predominated
in the left ventricles (LVs) of the Rbm201RRM heterozygotes
and homozygotes, respectively, and alternative splicing of the
Camk2d and Ldb3 genes was evidently affected as in the
Rbm20-deficient rats (Methawasin et al., 2014), indicating that
the RRM domain is crucial for the splicing regulation of
these genes in vivo. However, the heterozygous or homozygous
Rbm201RRM mice did not show any significant differences in
cardiac chamber geometry and dimensions compared to wild-
type controls (Methawasin et al., 2014), suggesting that switching
of the titin isoforms to N2BA-G together with the splicing
change in Camk2d and Ldb3 per se does not cause DCM-
like phenotypes such as LV chamber dilatation and systolic
dysfunction. This is consistent with that there is not a reported
familial case where a missense mutation is mapped to the
RRM domain (Table 1). Interestingly, the phenotypes of the
Rbm201RRM mice are distinct from those of the Rbm20-deficient
rats (Guo et al., 2012) and Rbm20 knockout (KO) mice in
which exons 4 and 5 are deleted for a frame-shift (van den
Hoogenhof et al., 2018): the heterozygous and homozygous
Rbm20 null rats and mice showed LV dilatation in addition
to drastic splicing changes in the Ttn, Camk2d and Ldb3
genes. These observations suggest that RBM20(1RRM) protein
retains some regulatory functions. Elucidation of transcripts
differentially affected between the Rbm201RRM and Rbm20
KO mice would lead to identification of genes crucial for
the progression of the DCM-like phenotypes in the rodent
models.
The only RBM20 missense mutation outside of the RSRSP
stretch in familial DCM cases with complete penetrance was
mapped to a highly conserved glutamate (E) residue in the E-
rich region (Beqqali et al., 2016; van den Hoogenhof et al.,
2018; Table 1). The E913K mutation has been shown to decrease
the amount of total RBM20 protein and to affect the TTN
splicing in the heart of a patient heterozygous for the mutation
(Beqqali et al., 2016), suggesting that the E-rich region is
crucial for the stability of RBM20. Other missense mutations
outside of the RSRSP stretch were identified only in sporadic
cases (Table 1) and no experimental evidence of altered splicing
has been demonstrated. Therefore, it is unclear whether these
mutations affected RBM20 functions and hence caused the DCM
phenotypes.
The only RBM20 non-sense mutation in the DCM patients
reported so far is G1031X in sporadic cases (Table 1). This
mutation is in exon 11 and likely causes non-sense-mediated
mRNA decay (NMD) of mature mRNAs (Schweingruber et al.,
2013), leading to haploinsufficiency of RBM20. Notably, one of
the patients is homozygous for the G1031X mutation due to
uniparental disomy, whereas his mother is asymptomatic even
with the heterozygous G1031Xmutation (Murayama et al., 2018).
It is therefore under debate whether heterozygous non-sense
mutations in RBM20 leading to haploinsufficiency would cause
the DCM phenotypes.
ANALYSIS OF THE RBM20 FUNCTIONS
WITH PLURIPOTENT STEM CELLS
Expression profiling throughout in vitro cardiogenesis in
embryoid bodies (EBs) derived from mouse embryonic stem
cells (mESCs) revealed that Rbm20 became expressed as early
as Nkx2-5, a marker for cardiac progenitors, consistent with
Rbm20 induction during in vivo cardiogenesis between E7.5 and
E8.5 (Beraldi et al., 2014). Even though Rbm20 is maximally
expressed at day 9 of in vitro differentiation, the transition of
the titin isoforms was apparent at day 24, which was suppressed
by Rbm20 knockdown (Beraldi et al., 2014), suggesting that
RBM20-mediated splicing regulation is reproduced in the in vitro
cardiogenesis.
In vitro differentiation of human induced-pluripotent
stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs) from
familial DCM patients carrying different RBM20 mutations
have been utilized for gene expression profiling during in
vitro cardiogenesis. Cytological analysis of the hiPSC-CMs
revealed that the RBM20 mutations disorganized sarcomere
structures (Wyles et al., 2016b; Streckfuss-Bömeke et al., 2017).
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The RBM20 hiPSC-CMs were defective in Ca2+ handling
machinery with prolonged Ca2+ levels in the cytoplasm and
higher Ca2+ spike amplitude (Wyles et al., 2016b; Streckfuss-
Bömeke et al., 2017), consistent with an increased risk of
malignant ventricular arrhythmias in DCM patients with
RBM20 mutations than those with TTN mutations (van den
Hoogenhof et al., 2018). The RBM20 hiPSC-CMs have also
been utilized for demonstrating their increased susceptibility
to β-adrenergic stress and therapeutic rescue by a β-blocker
carvedilol and a Ca2+ channel blocker verapamil (Wyles et al.,
2016a).
REGULATION OF TITIN COMPLIANCE BY
RBM20
Titin-based passive tension in the cardiomyocytes occupies a
large proportion of the passive stiffness of the whole myocardium
(Rivas-Pardo et al., 2016). It has a negative correlation with
molecular weight or amino acid sequence length of titin’s
spring region. For instance, N2B has a shorter elastic region
compared to N2BA, thus giving higher passive stiffness to the
cardiomyocytes. It is therefore believed that the ratio of the titin
isoforms as well as the total amount of titin protein influence
the myocardial passive stiffness (Lahmers et al., 2004). The
ratio of the N2B isoform to the N2BA isoform varies from
species to species (Neagoe et al., 2003) and from ventricles
to atria (Fukuda et al., 2003). It is also dynamically regulated
during development (Lahmers et al., 2004; Opitz et al., 2004;
Warren et al., 2004; Opitz and Linke, 2005; Figure 2B) and
under pathological conditions. Amount of the N2BA isoformwas
increased in heart failure with DCM, heart failure with reduced
ejection fraction (HFrEF) and chronic ischemic cardiomyopathy
(Makarenko et al., 2004; Nagueh et al., 2004; Borbély et al., 2008),
and a reduction of the N2BA isoform was observed in diastolic
dysfunction resulting from hypertensive heart disease (Warren
et al., 2003).
In the Rbm201RRM heterozygote mice, the compliance of
titin proteins is increased and diastolic stiffness of a LV
chamber is reduced without significant effect on the chamber
geometry or dimensions; beneficial effects on diastolic function
dominated under conditions of exercise over an unfavorable
effect on end-systolic elastance (Methawasin et al., 2014). Splicing
changes in the Ldb3 and Camk2d genes in the Rbm201RRM
heterozygotes caused minimal effects on the LDB3 isoforms
and no apparent effects on phosphorylation of known CaMKII-
δ targets (Methawasin et al., 2014). The Rbm201RRM mice
have therefore been utilized to prove a concept that increasing
the titin compliance is beneficial to disease models where the
mice suffer from lowered diastolic stiffness of the hearts (see
below).
RBM20 AS A POTENTIAL THERAPEUTIC
TARGET
Heart failure with preserved ejection fraction (HFpEF) is
a complex syndrome that includes diastolic dysfunction,
exercise intolerance and concentric hypertrophic remodeling.
Deletion of Ttn exons 251–269, corresponding to the I-band–
A-band junction (IAjxn) of titin, increases strain on the
spring region and causes an HFpEF-like syndrome in mice
(Granzier et al., 2014). Upon constitutive or inducible, heart-
specific heterozygous deletion of the RBM20 RRM domain in
the Ttn1IAjxn mice, compliant titin isoforms were expressed,
diastolic function was normalized, exercise performance was
improved and pathological hypertrophy was attenuated (Bull
et al., 2016). HFpEF model mice can also be prepared
by performing transverse aortic constriction (TAC) surgery
with deoxycorticosterone acetate (DOCA) pellet implantation;
inducible, heart-specific heterozygous deletion of the RRM
domain in this model mice has also been shown to ameliorate
diastolic dysfunction and to recover exercise intolerance
(Methawasin et al., 2016).
Deletion of Ttn exon 49, corresponding to the N2B-unique
element, results in small hearts with reduced sarcomere length
and increased passive tension leading to diastolic dysfunction in
mice (Radke et al., 2007). Heterozygous deletion of the RBM20
RRM domain from the Ttn N2B KO mice restored the cardiac
dimension and improved the diastolic function (Hinze et al.,
2016).
Deletion of Ttn constitutive exons 30–38, corresponding to
nine proximal Ig domains in the spring region, increased diastolic
stiffness leading to diastolic dysfunction (Chung et al., 2013)
and caused mild kyphosis, a phenotype associated with skeletal
muscle myopathy (Buck et al., 2014) in mice. RBM20 was
upregulated at the protein level in the Ttn IG KO soleus muscle
leading to further shortening of titin and heterozygous deletion
of the RBM20 RRM domain from the Ttn IG KO mice restored
the length of titin in the soleus (Buck et al., 2014).
These examples demonstrated that diastolic dysfunctions
could be rescued by increasing titin compliance through
manipulation of Ttn pre-mRNA splicing in the animal models,
and raised the Ttn splicing regulator RBM20 as a potential
therapeutic target. Recently, high-throughput screening of small
compounds were performed with RBM20-sensitive TTN splicing
reporters and cardenolides have been shown to inhibit RBM20-
mediated repression of TTN exons at least in part by reducing
RBM20 protein level in cultured cells (Liss et al., 2018).
Extracellular and intracellular signals affecting the titin
isoform ratios via RBM20 have also been investigated.
Thyroid hormone T3 can promote developmental titin
isoform transitions in primary rat cardiomyocytes via the
phosphatidylinositol-3-kinase (PI3K)/AKT pathway (Krüger
et al., 2008) and the effect of T3 on titin is dependent on RBM20
(Zhu et al., 2015). Western blot analysis of the cardiomyocytes
with anti-RBM20 antibody detected two bands with apparent
molecular weight of 135 kDa and 145 kDa and the amounts of
the two isoforms were differentially affected by T3 and/or a PI3K
inhibitor, implying that the activity of RBM20 is regulated by
post-translational modification(s) (Zhu et al., 2015). Insulin can
also promote the developmental transition of the titin isoforms
in primary rat cardiomyocytes by increasing the amount of
RBM20 proteins through the PI3K-Akt-mTOR kinase axis (Zhu
et al., 2017).
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REGULATION OF CIRCULAR RNA
PRODUCTION FROM THE TTN GENE BY
RBM20
Circular RNAs (circRNAs) can be generated by “back-splicing”
of pre-mRNAs (Li et al., 2018) and some of the circRNAs have
physiological functions as miRNA sponges in vivo (Hansen et al.,
2013; Memczak et al., 2013). The TTN gene has been shown
to produce a variety of circRNAs mostly from the alternatively
spliced exons (Li et al., 2013; Khan et al., 2016). Recent RNA-
seq experiments identified thousands of circRNAs in the human
heart (Khan et al., 2016) and>1,000 circRNAs in themouse heart
(Aufiero et al., 2018). However, only a small subset of circRNAs
expressed in the heart are evolutionarily conserved (Aufiero et al.,
2018), implying that most of the cardiac circRNAs are non-
functional. Forty-three of the human cardiac circRNAs including
those from the TTN and CAMK2D genes were differentially
expressed in heart samples from DCM patients compared with
those from controls (Khan et al., 2016). Thirty-eight of the mouse
cardiac circRNAs were differentially expressed in the Rbm20
KO mice, 11 of which were generated from the Ttn gene in
an RBM20-dependent manner (Aufiero et al., 2018). One may
therefore say that RBM20 switches from N2BA-G production to
circRNA production from the TTN gene, although physiological
and pathological functions of the circRNAs from the TTN and
other genes remain to be elucidated.
OPEN QUESTIONS AND FUTURE
RESEARCH DIRECTIONS
Although it has been genetically shown that the RBM20
mutations cause DCM, subsequent cardiac transcriptome
analyses and animal models have not yet specified RBM20-
regulated genes whose aberrant splicing are critically linked
to each of the DCM symptoms such as systolic dysfunction,
left ventricle dilatation and a risk of ventricular arrhythmia.
RBM20 mutant protein with a missense mutation in the
RSRSP stretch may exert aberrant functions in the cytoplasm
(Figure 3). Identification of such critical splice variants or
aberrant effects may lead to development of new therapeutics for
DCM symptoms not restricted to those caused by the RBM20
mutations. To validate the candidate events, it is necessary
to genetically restore cardiac isoforms and/or reduce aberrant
isoforms in an appropriate animal model that show DCM-like
phenotypes as in the RBM20-linked DCM patients. Ventricular
arrhythmia has not been reported for the 1RRM or KO mouse
models, and therefore another animal model that phenocopies
the RBM20-linked DCM is awaited. A recent large-scale genome-
wide association study (GWAS) of >1 million people including
60,620 atrial fibrillation cases have identified RBM20 as one of
genes near risk variants (Nielsen et al., 2018), suggesting its
implication in atrial cardiomyopathy.
TTN exons 51–124 and alternative splicing events in
CAMK2D and LDB3 are hyper-sensitive to reduction in the
amount of functional RBM20 protein, whereas TTN exons
125–218 are much less affected by the heterozygous mutations
(Guo et al., 2012; Beqqali et al., 2016; Murayama et al.,
2018). Biochemical and biophysical analysis of the splicing
control of TTN by RBM20 should address the following
points: (1) how tens of consecutive cassette exons can be
synchronously repressed depending on the amount of a single
factor RBM20, and (2) how other tens of consecutive cassette
exons can be almost completely repressed by less amount
of RBM20. Application of recent technical progress in direct
sequencing of full-length cDNA/mRNA to the extremely long
TTN transcripts would elucidate precise splicing patterns of the
RBM20-dependent isoforms, which will help understanding the
regulation mechanisms.
RBM20 is expressed at early cardiogenesis, yet a compliant
titin FCT isoform is expressed in the embryonic heart. RBM20
is also expressed in the skeletal muscle, yet the splicing patterns
of the TTN mRNAs are totally different between these tissues.
So far, it is unknown how the activity of RBM20 is regulated
during development and in different tissues. Elucidating such
mechanisms will lead to further understanding of heart-specific
alternative splicing regulation as well as to future possible
therapeutics that manipulate the activity of RBM20.
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